Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

NCT07267338 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

NPC
Locoregionally Advanced Nasopharyngeal Carcinoma

Interventions

DRUG: Pembrolizumab & MRG003

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborators

Merck Sharp & Dohme LLC
Lepu Medical Technology (Beijing) Co., Ltd.